Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma
Authors:
- María PozaMPMaría Poza
- Alejandro Martin-MuñozAMAlejandro Martin-Muñoz
- Patricia López-PereiraPLPatricia López-Pereira
- Gloria FigaredoGFGloria Figaredo
- Irene ZamanilloIZIrene Zamanillo
- Rodrigo ÍñiguezRÍRodrigo Íñiguez
- Ana Carla OliveiraAOAna Carla Oliveira
- Tycho BaumannTBTycho Baumann
- Antonia Rodríguez-IzquierdoARAntonia Rodríguez-Izquierdo
- Carlos GrandeCGCarlos Grande
- Pilar SarandesesPSPilar Sarandeses
- Enrique RevillaEREnrique Revilla
Open Access
Abstract
Background/Objectives: This study aimed to determine whether interim PET/CT (iPET) scans could identify follicular lymphoma (FL) patients at high risk of relapse following first-line therapy. Methods: A total of 117 FL patients who underwent iPET scans were included, with responses interpreted using the Deauville score (DS). Progression-free survival (PFS) was evaluated over a median follow-up of 34 months. Results: Overall, 34% of patients were classified as iPET (+), with significantly worse estimated 5-year PFS compared to iPET (−) patients (34% vs. 76%, hazard ratio 4.3, p < 0.001). Multivariate analysis confirmed iPET (+) as an independent predictor of PFS. Conclusions: Interim PET results are significant predictors of PFS in FL first-line therapy and could inform response-adapted treatment strategies.Keywords
All Related Versions
Funding Information
- Instituto de Salud Carlos III (PI21/00314, PI23/01864, CP22/00082)
- European Union (PI21/00314, PI23/01864, CP22/00082)
- CRIS Cancer Foundation (PI21/00314, PI23/01864, CP22/00082)
This publication has 46 references indexed in Scilit:
- Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular LymphomaHemaSphere, 2023
- Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CTLeukemia, 2023
- Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular LymphomaNuclear Medicine and Molecular Imaging, 2019
- NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMAHematological Oncology, 2019
- PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 studyThe Lancet Oncology, 2019
- Rituximab plus Lenalidomide in Advanced Untreated Follicular LymphomaNew England Journal of Medicine, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- The prognostic value of mid- and post-treatment [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphomaAnnals of Nuclear Medicine, 2014
- Positron Emission Tomographic Scans in Lymphoma: Convention and ControversyMayo Clinic Proceedings, 2012
- Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphomaLeukemia & Lymphoma, 2007